CureVac

CVAC

Market cap $1.2B

Overview Fund Activity

5.36 USD

+0.01

0.19%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

5.34

-0.02

0.37%

1 day

0.19%

5 days

0%

1 month

-1.65%

3 months

-2.55%

6 months

74.59%

Year to date

55.36%

1 year

63.41%

5 years

-89.87%

10 years

-90.41%

About: CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,088

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

186% more capital invested

Capital invested by funds: $21.8M [Q1] → $62.5M (+$40.6M) [Q2]

56% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 16

10% more funds holding

Funds holding: 83 [Q1] → 91 (+8) [Q2]

1.69% more ownership

Funds ownership: 3.51% [Q1] → 5.2% (+1.69%) [Q2]

0% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 25

37% less call options, than puts

Call options by funds: $1.83M | Put options by funds: $2.9M

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5.5

3% upside

Avg. target

$5.5

3% upside

High target

$5.5

3% upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

UBS

Eliana Merle

$5.5

Neutral

Downgraded

26 Jun 2025

See Analyst Rankings

Financial journalist opinion

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pending patent litigation in the U.S. with Pfizer/BioNTech related to mRNA-based COVID-19 vaccines and to set a framework for resolving related ongoing patent disputes outside the U.S. upon closing of BioNTech's acquisition of CureVac Received Clinical Trial Application (CTA) clearance from the European Medicines Agency (EMA) for CVHNLC, a proprietary off-the-shelf cancer immunotherapy candidate targeting squamous non-small cell lung cancer (sqNSCLC) CVGBM glioblastomadata from Part B of Phase 1 remain on track for H2 2025 Strong cash and cash equivalents position of €392.7 million as of June 30, 2025; expected cash runway into 2028 TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / August 15, 2025 / CureVac N.V. (Nasdaq:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced financial results for the second quarter and first half of 2025 and provided a business update.

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates

Proactive Investors

GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

GSK PLC (LSE:GSK, NYSE:GSK) will receive an upfront payment of $370 million from CureVac, following a patent settlement involving BioNTech and Pfizer over messenger ribonucleic acid (mRNA) vaccine technology. The deal will also see GSK collect a 1% royalty on United States sales of Pfizer and BioNTech's influenza, COVID-19, and related combination mRNA vaccines from the start of 2025.

GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

CureVac settles patent dispute litigation with Pfizer and BioNTech

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

CureVac settles patent dispute litigation with Pfizer and BioNTech

CureVac Announces Voting Results of General Meeting

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today announced the voting results of the Company's Annual General Meeting.

CureVac Announces Voting Results of General Meeting

Zacks Investment Research

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CureVac N.V. (NASDAQ: CVAC ) related to its sale to BioNTech SE. Under the terms of the proposed transaction, each CureVac share will be exchanged for approximately $5.46 in BioNTech ADSs. Upon closing of the proposed transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. Is it a fair deal?

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of CureVac N.V. (NASDAQ: CVAC)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow Jones Industrial Average was lower.

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

Schaeffers Research

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

CureVac Stock Soars on BioNTech Buyout

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

See News Rankings

Charts implemented using Lightweight Charts™